MedAdvisor posts increased loss in ‘pivotal’ year

But medtech company looks to the future as revenue increases significantly ASX-listed medication adherence company MedAdvisor has reported an increased loss after tax for FY22 of close to $17.5 million, an increase on its $14.37 million loss for FY21. But the company also delivered revenue of $67.8 million, a significant 75 per cent increase on